Open AccessExtraordinary Survival Benefits of Severe and Critical Patients with COVID-19 by Immune Modulators: The Outcome of a Clinical Trial in Bangladesh
Author(s) -
Akm Monwarul Islam,
Masudul A Mazumder,
Neelima Akhter,
Akm Faizul Huq,
Mamun AlMahtab,
Sakirul Khan,
Sk. Md. Fazle Akbar
Publication year - 2021
Publication title -
euroasian journal of hepato-gastroenterology
Language(s) - English
Resource type - Journals
eISSN - 2231-5128
pISSN - 2231-5047
DOI - 10.5005/jp-journals-10018-1327
Subject(s) - medicine , tocilizumab , intensive care unit , pneumonia , covid-19 , clinical trial , coagulopathy , viral pneumonia , immune system , intensive care medicine , immunology , disease , infectious disease (medical specialty)
Coronavirus disease (COVID)-19 has devasted the healthcare delivery system as well as social establishments of almost all countries of the world. However, vaccines for containing new cases of COVID-19 are yet to be realized. Also, presently available antiviral drugs and other standard of care (SOC) management strategies could not satisfactorily control COVID-19-related mortality, which has crossed the one million mark during the last 9 months. These facts present an emergent need for developing new, novel, and evolving therapeutic strategies for the management of COVID-19.